Other substances

Levamisole

An antiparasitic.

Phase of research

Potential treatment - clinical evidence

How it helps

Antiviral

Drug status

Used to treat other disease

1
 Supporting references
0
 Contradictory references
3
 AI-suggested references
3
 Clinical trials

General information

Levamisole is an anthelmintic drug. It is also used as and adjuvant in the cancer treatment due to its immunomodulatory properties (NCIt).

Levamisole on DrugBank
Levamisole on PubChem
Levamisole on Wikipedia


Marketed as

ERGAMISOL; KETRAX

 

Structure image - Levamisole

C1CSC2=N[C@H](CN21)C3=CC=CC=C3

Supporting references

Link Tested on Impact factor Notes Publication date
Efficacy and safety of Levamisole treatment in clinical presentations of non-hospitalized patients with COVID-19: a double-blind, randomized, controlled trial
Small molecule Randomized controlled double-blind trial 		Outpatients 2.69

Statistically significant improvement in cough status (on days 3 and 14) and dyspnoea (on days 7 and 14) were observed in the treatment group compared to control. No significant difference was observed in other clinical parameters or at different time points. The drug is generally safe. Sample size: 25 + 25 placebo. Dosage: 50 mg three times a day for 3 days.


 Mar/24/2021

AI-suggested references

Link Publication date
Levamisole Therapy in COVID-19.
Dec/13/2021
Can Levamisole be used in the treatment of COVID-19 patients presenting with diarrhea?
Aug/31/2020
Molecular docking, molecular dynamics simulation, and ADMET analysis of levamisole derivatives against the SARS-CoV-2 main protease (MPro)
Sep/18/2021

Clinical trials

ID Title Status Phase Start date Completion date
NCT04360122 Levamisole and Isoprinosine in Immune-prophylaxis of Egyptian Healthcare Workers Facing COVID-19 Not yet recruiting Phase 3 May/20/2020 Dec/01/2020
  • Alternative id - FMASU P20a/ 2020
  • Interventions - Drug: Levamisole|Drug: Isoprinosine|Drug: Levamisole and Isoprinosine
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Faculty of Medicine Ain Shams University Research Institute- Clinical Research Center, Cairo, Non-US, Egypt
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention
  • Enrollment - 100
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - Decrease the incidence of COVID-19 infection or its severity
NCT04331470 Evaluation of Efficacy of Levamisole and Formoterol+Budesonide in Treatment of COVID-19 Recruiting Phase 2|Phase 3 Apr/04/2020 May/20/2020
  • Alternative id - 97548
  • Interventions - Drug: Levamisole Pill + Budesonide+Formoterol inhaler|Drug: Lopinavir/Ritonavir + hydoxychloroquine
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Vali-Asr Hospital, Fasa, Fars, Iran, Islamic Republic of
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment
  • Enrollment - 30
  • Age - 15 Years to 100 Years   (Child, Adult, Older Adult)
  • Outcome measures - Clear chest CT-scan|PCR test|Physical statues of patient
NCT04383717 Levamisole and Isoprinosine in the Treatment of COVID19: A Proposed Therapeutic Trial Not yet recruiting Phase 3 May/05/2020 Oct/30/2020
  • Alternative id - Levamisole and isoprinosine
  • Interventions - Drug: Levamisole and isoprinosine|Drug: Azithromycin and hydroxychloroquine
  • Study type - Interventional
  • Study results - No Results Available
  • Locations -
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment
  • Enrollment - 60
  • Age - 6 Years to 90 Years   (Child, Adult, Older Adult)
  • Outcome measures - COVID 19 induced fever in both groups|COVID 19 induced dyspnea in both groups|COVID 19 viral load in both groups|laboratory clearance in both groups: CRP in mg/dL
Export (.csv)